Clinical Trial Update: Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial comparing intravenous versus intracoronary abciximab in patients undergoing primary PCI for STEMI has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• St-elevation Myocardial Infarction

Drugs mentioned

• Abciximab (abciximab)

Snippet

Sponsor: University of Leipzig | Conditions: Myocardial Infarction | Phase 2, Phase 3 | Status: COMPLETED